Roche Spends $451 Million to Acquire Inflazome’s NLRP3 Program
The deal will provide the pharma giant with a unique new platform for tackling autoimmune diseases.
Roche Spends $451 Million to Acquire Inflazome's NLRP3 Program
Tweet on Twitter
Share on Facebook
Google+
Pinterest
